A detailed history of Armistice Capital, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Armistice Capital, LLC holds 181,381 shares of NBIX stock, worth $22.8 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
181,381
Previous 978,488 81.46%
Holding current value
$22.8 Million
Previous $135 Million 84.5%
% of portfolio
0.35%
Previous 1.75%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$114.58 - $153.15 $91.3 Million - $122 Million
-797,107 Reduced 81.46%
181,381 $20.9 Million
Q2 2024

Aug 14, 2024

SELL
$130.86 - $143.19 $5.92 Million - $6.48 Million
-45,251 Reduced 4.42%
978,488 $135 Million
Q1 2024

May 15, 2024

SELL
$130.4 - $143.74 $3.16 Million - $3.49 Million
-24,261 Reduced 2.31%
1,023,739 $141 Million
Q4 2023

Feb 13, 2024

SELL
$106.07 - $132.76 $17.9 Million - $22.4 Million
-168,365 Reduced 13.84%
1,048,000 $138 Million
Q3 2023

Nov 14, 2023

SELL
$94.02 - $117.1 $40.8 Million - $50.8 Million
-433,635 Reduced 26.28%
1,216,365 $137 Million
Q2 2023

Aug 14, 2023

BUY
$89.53 - $104.87 $5.19 Million - $6.08 Million
58,000 Added 3.64%
1,650,000 $156 Million
Q1 2023

May 15, 2023

BUY
$94.11 - $123.02 $65.1 Million - $85.1 Million
692,000 Added 76.89%
1,592,000 $161 Million
Q4 2022

Feb 14, 2023

SELL
$106.72 - $127.06 $45.2 Million - $53.9 Million
-424,000 Reduced 32.02%
900,000 $107 Million
Q2 2022

Aug 15, 2022

BUY
$75.79 - $100.07 $51.1 Million - $67.4 Million
674,000 Added 103.69%
1,324,000 $129 Million
Q1 2022

May 16, 2022

BUY
$72.45 - $94.81 $47.1 Million - $61.6 Million
650,000 New
650,000 $60.9 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.